on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed Form 8.3 under the Irish Takeover Panel Act, 1997. This disclosure identifies Vanguard's interests in Avadel Pharmaceuticals plc. The significant date noted is 29 October 2025. Vanguard controls 5,518,512 ordinary shares, representing a 5.67% stake. This document marks an opening position disclosure regarding Avadel Pharmaceuticals’ shares.
Vanguard executed limited trading activities, purchasing 285 shares and selling 6,955, both transactions priced at $18.90 per share. No additional financial instrument dealings, such as derivatives, were reported. The disclosure indicates no indemnity or other dealing agreements, nor are there attachments in the form of Supplemental Form 8.
Overall, this disclosure aligns with Rule 8.3 mandates, focusing on significant shareholders in target companies during takeover periods.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news